TCWM
BCTX

Total Clarity Wealth Management’s Briacell Therapeutics BCTX Stock Holding History

Total Clarity Wealth Management’s Portfolio BCTX Stock Details BCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-21
Closed -$18K – 288
2022
Q2 		$18K Buy
+21
New +$20.8K 0.01% 565
2022
Q1 		– Sell
-105
Closed -$131K – 276
2021
Q4 		$131K Buy
105
+29
+38% +$38K 0.06% 276
2021
Q3 		$93K Buy
+76
New +$69.9K 0.04% 314

Other funds holding BCTX

LCM
Lynwood Capital Management Toronto, Ontario, Canada $16.9M AUM 19.31% 1-Year Est. Return
KJHP
K.J. Harrison & Partners Toronto, Ontario, Canada $608M AUM 45.31% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
RAM
Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
STA
Summit Trail Advisors New York $6.98B AUM 19.51% 1-Year Est. Return
AWM
Apollon Wealth Management Mount Pleasant, South Carolina $8.23B AUM 30.88% 1-Year Est. Return
CWP
Concord Wealth Partners Abingdon, Virginia $873M AUM 24.02% 1-Year Est. Return

Total Clarity Wealth Management's BCTX Position: Q3 2022 in Review

Total Clarity Wealth Management sold out of Briacell Therapeutics (BCTX) in Q3 2022, closing a stake of 21 shares — an estimated $18K sold.

Total Clarity Wealth Management first reported a position in BCTX in Q3 2021 and held it in 3 quarters. The position peaked at $131K in Q4 2021. 18 funds tracked by Wall St. Rank hold BCTX as of Q3 2022.

  • Total Clarity Wealth Management reported no remaining Briacell Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Total Clarity Wealth Management sold 21 Briacell Therapeutics shares in Q3 2022, an estimated $18K.
  • Total Clarity Wealth Management first reported a position in Briacell Therapeutics in Q3 2021 and held it in 3 quarters.
  • Total Clarity Wealth Management's Briacell Therapeutics position peaked at $131K in Q4 2021.
  • 18 funds tracked by Wall St. Rank held Briacell Therapeutics as of Q3 2022.

Based on Total Clarity Wealth Management's 13F filing for Q3 2022, filed 4 Nov 2022.